Expert Perspectives: Anti-Angiogenesis and Immune Therapy for Cancer

Over the past 2 decades, enormous progress has been made in understanding the complex interactions between tumors and the immune system, and in developing innovative ways to manipulate antitumor responses. In tumor cells angiogenesis is a fundamental process to tumor growth; inhibiting this process has led to approval of therapies that inhibit this process—most prominent among them are agents that interfere with the vascular endothelial growth factor (VEGF) pathway. More recently, therapies that help immune system cells suppress tumor growth have come to the fore, specifically therapies that are antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) which release the brakes on the immune response, allow T cells to expand, produce cytokines, and carry out their normal effector functions. Because the growth of clinical research in these areas—anti-angiogenic therapy and immunotherapy—has been so impressive and rapid, oncologists are challenged with keeping pace with ongoing developments. This e-learning activity is designed to help take advantage of our improved understanding of innovations in antitumor strategies and to overcome the challenges that have limited the potential of cancer therapy in the past.

Earn accreditation for this activity at the following location:
http://elc.imedex.com/Shared/Services...

© 2015 Imedex, LLC.